Regeneron (REGN) First-Quarter Earnings Show 19% Revenue Growth
Published on · Source: finance.yahoo.com

AI Summary
Summarized by AI from the source belowRegeneron Pharmaceuticals (REGN) posted first-quarter revenue of $3.6 billion, a 19% increase year-over-year, surpassing analysts' expectations of $3.48 billion. Despite a 10% drop in Eylea sales to $941 million, Libtayo sales surged 54% to $438 million, and Dupixent sales reached $1.6 billion, up 36%. The company also initiated a new $3 billion share repurchase program following an $803 million buyback in Q1. Additionally, the FDA granted accelerated approval for Otarmeni, a gene therapy for hearing loss, further enhancing Regeneron's market potential.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Regeneron Pharmaceuticals (REGN)
Regeneron is a biotechnology company known for Eylea and Dupixent.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier REGN news
- Regeneron (REGN) Offers Otarmeni Gene Therapy Free in U.S.
- Regeneron (REGN) drug pricing deal lowers costs, offers free therapy
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.



